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Abstract
Background—Two prominent challenges in nursing home care are ensuring appropriate
medication use and achieving high quality care as residents transition from the hospital to the
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nursing home and back. Research about prescribing practices at this important clinical juncture is
limited.
Objective—To analyze the use of high-risk medications by nursing home residents before and
after being hospitalized. We define high-risk medications using the Beers criteria for potentially
inappropriate medication use.
Research Design, Subjects, Measures—Using a dataset with Medicare claims for inpatient
and skilled nursing facility stays, and pharmacy claims for all medications dispensed in the
nursing home setting, we examine high-risk medication use for hospitalized nursing home
residents before and after being hospitalized. Our study population includes 52,559 dual-eligible
nursing home residents aged 65 and older who are hospitalized and then readmitted to the same
nursing home in 2008. Our primary outcome of interest is the use of high-risk medications in the
30 days before hospitalization and the 30 days following readmission to the same nursing home.
We define high-risk medications using the Beers criteria for potentially inappropriate medication
use.
Results—Around one in five hospitalized nursing home residents (21%) used at least one high-
risk medication the day before hospitalization. Among individuals with high-risk medication use
at hospitalization, the proportion using these medications dropped to 45% after nursing home
readmission but increased thereafter, to 59% by the end of the 30-day period.
Conclusion—We found moderate levels of high-risk medication use by hospitalized nursing
home residents before and after their hospital stays, constituting an important clinical and policy
challenge.
Keywords
Nursing home; high-risk medication use; care transitions; elderly; dual eligible
INTRODUCTION
Two prominent policy challenges related to care of nursing home residents are ensuring
appropriate medication use and high quality care as residents transition from the hospital to
the nursing home and back. Research studies, media coverage, and government reports have
highlighted challenges and opportunities in each of these areas, with payment and regulatory
reforms focusing accordingly.(1–5) Improving residents’ care following hospital discharge
and aligning incentives for providers to do so has been a guiding principle for bundled
payment initiatives and accountable care organizations alike, especially around reducing
avoidable hospitalizations.(6) Minimizing high-risk medication use in the nursing home has
been an important issue for policymakers and providers for more than a decade, with these
initiatives gaining greater traction and achieving greater success recently in the area of
antipsychotic prescribing.(7)
Despite the prominent focus in each of these two areas, there has been little work at their
intersection, namely to analyze high-risk prescribing practices as individuals transition
across care settings. Research on this topic has been inhibited by the lack of data on
pharmacy claims as people transition from one setting to another. Obtaining pharmacy
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claims from Medicare inpatient and skilled nursing facility stays is especially challenging, as
separate administrative claims for services included in providers’ bundled payments are
unavailable. One exception is a strand of research focused on medication reconciliation
between the hospital and nursing home that examines prescribing consistency across
settings. Typically focused on limited samples of hospitals and nursing homes, these studies
have identified medication discrepancies in the majority of discharges, noting that many of
them are unintentional and can result in adverse drug events.(8–10) Other analyses have
found substantial gaps in communication during care transitions, many of which center on
medication use and require iterative steps between nursing home and hospital staff to
resolve.(11, 12)
In this paper we analyze the use of high-risk medications by nursing home residents before
and after being hospitalized. Comparing pre- and post-hospitalization periods provides a
unique window into nursing home prescribing and in particular whether residents start,
restart, or discontinue high-risk medications following hospital stays. We define high-risk
medications by referencing Beers list criteria available during our study period for such
medication use among older patients (described below). We take advantage of a rich data set
from a large national sample of nursing home residents that includes all medications
dispensed in the nursing home setting, regardless of payer.
METHODS
Design Overview
The study links the following datasets: resident demographic characteristics from Medicare
Beneficiary Summary files; inpatient hospital claims from MedPAR files; and pharmacy
claims from Omnicare, including those paid by Medicare (including those prescribed during
a Part A Medicare-financed skilled nursing facility stay), Medicaid, and other payers. The
pharmacy claims data included a unique resident identification number to allow for
longitudinal tracking and linkage to other datasets and contained various elements about the
medications for which claims were made, including payer information, National Drug Code
(NDC), drug name, days supplied, an indicator for whether a copayment was paid on the
claim, the date the prescription was written, and the date the prescription was filled. These
pharmacy claims should accurately reflect dispensed medications since they are adjudicated
online and incorporate subsequent corrections, where applicable (e.g., because of rejected
claims). We include resident hospitalizations between January 1, 2008 and December 1,
2008, capturing pre-hospitalization medication use from December 1, 2007 and post-nursing
home readmission medication use to December 31, 2008. We focus on medication use
surrounding residents’ first hospitalization during this time period.
Setting and Participants
Our study population includes dual-eligible (traditional Medicare and Medicaid) nursing
home residents aged 65 and older who were hospitalized and then readmitted to the same
nursing home following discharge in 2008 (verified by a nursing home’s Medicare provider
number, included in the pharmacy claims data). We focus on residents’ first hospitalization
during the study period only. Because we condition on residents returning to the same
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facility and residing therein for the full 30-day observation period, our population is
predominantly a long-stay nursing home population. The residents in our study lived in
facilities that contracted with Omnicare as their long-term care pharmacy (LTCP) provider,
all of which were included in the study’s sample frame. Omnicare is the largest LTCP in the
U.S, serving almost 50 percent of nursing home residents nationwide during the study
period.
Outcomes
Our primary focus is on the use of high-risk medications in the 30 days before
hospitalization and the 30 days following readmission to the same nursing home. We define
high-risk medications using the Beers criteria for potentially inappropriate medication use.
Originally developed in the early 1990s, the Beers criteria evaluated the appropriateness of
prescribed medications in nursing home residents, explicitly noting the use of high-risk
medications for the elderly for which safer alternatives exist.(13) These criteria were
updated in 1997(14) to include potentially inappropriate prescribing for community-
dwelling elderly patients and again in 2003(15) to incorporate greater specificity about
medication dosage and patient conditions. A further updated version of the Beers list,
published in 2012,(16) incorporated clinical information and refined identification methods
to categorize high-risk medications.
We present results based on the use of any medications included on the 2003 Beers list that
was current at the time of the study data (2008), focusing on medications broadly identified
as high-risk independent of diagnosis or condition (i.e., Table 1 of Frick et al, 2003(15)). For
a subset of these medications, prescribed dosage levels must be above the threshold
specified in the Beers criteria to be labeled as high-risk (e.g., ferrous sulfate is only labeled
high risk when prescribed at dosages above 325 mg/day).
Statistical Analyses
We present demographic and other information about residents who are hospitalized and
then return to the same nursing home following discharge, including age, gender, and race;
major diagnostic categories at hospital admission and hospital length of stay; and medication
use on the day before hospital admission, including the total number of medications taken
and the proportion using high-risk medications (Table 1). We categorize residents as using
medications on a particular day if they have days supply remaining in their long-term care
pharmacy prescription. As per regulation, we assume all medications are discarded when a
resident is hospitalized and then again when they are readmitted to the same nursing home
after the hospital stay (i.e., days supply do not carry over from the pre- to post-
hospitalization periods or across the nursing home and hospital settings).
The next two figures display the proportion of residents using at least one high-risk
medication on each day during the 30 days before hospital admission and during the 30 days
subsequent to nursing home readmission. Figure 1 shows high-risk medication use across
these time periods among all hospitalized residents; Figure 2 displays high-risk medication
use across these time periods separately for people with and without high-risk medication
use on the day before hospitalization. We do not have information about residents’
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medication use in the hospital, denoted by the dashed vertical lines in each figure. As a
sensitivity check, we also estimated these Figures including residents who died or were
discharged during the 30-day post-readmission period in the study sample. Although these
discharged residents comprised a sizeable minority of all residents who were hospitalized
and then returned to the same facility (24%), these sensitivity analyses produced results that
were similar to the results that are presented (results not shown).
Finally, we present frequencies of the 10 most prescribed high-risk medications from the
2003 Beers list, among: i) residents with any high-risk medication use the day before
hospital admission; and ii) residents with high-risk medication use on day 3 and on day 30
following nursing home readmission, presented separately for residents who did and did not
have high-risk medication use on the day before admission to the hospital (Table 2). We
chose days 3 and 30 in the post-nursing home readmission period to assess whether
particular high-risk medications are started sooner or later and whether discharge or death of
residents later in the observation period affects our results.
RESULTS
Population and hospitalizations
Our study sample includes 52,559 dually eligible nursing home residents who were
hospitalized in 2008. Around 72% were female; 83% were age 75 and above; and 81% were
white. Around half of all hospitalizations fell into the major diagnostic categories of diseases
or disorders of the respiratory system (22%), circulatory system (15%), and kidney or
urinary tract (13%). The mean length of hospital stay was 5.61 days, with substantial
variation across the cohort (sd=4.46).
Medication Use
On the day before hospitalization, nursing home residents used 8.5 drugs on average, and
21% of the study sample had high-risk medication use. Although the proportion using high-
risk medications dipped marginally in the second week following readmission to the nursing
home, the level of high-risk medication use was stable over the pre-hospitalization and post-
readmission periods, generally hovering around 20% (Figure 1).
The pattern of use differed for those who did and did not have high-risk medication use on
the day before hospitalization (Figure 2). For those who did not have high-risk medication
use at hospitalization, there was an initial increase in use of these medications upon nursing
home readmission (up to 14% on days 3 to 5), followed by a relatively stable rate of use
subsequently of around 10%. For those who did have high-risk medication use on the day
before hospitalization, the proportion of these residents using high-risk medications dropped
to around 45% at day 3 and increased slowly thereafter, to 59% by the end of the 30-day
period.
Table 2 shows the frequency of high-risk medication use, based on the 2003 Beers list, on
the day before hospitalization and at days 3 and 30 for residents with and without high-risk
medication use when hospitalized, respectively. For residents who were already taking a
high-risk medication at the time of hospital admission, clonidine was the most prescribed
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high-risk medication both at hospitalization and at days 3 and 30 following nursing home
readmission. On the day before hospitalization, prescriptions for clonidine represented
14.7% of all high-risk medication prescriptions. The most frequently prescribed high-risk
medications to these residents over the same timeframe included amiodarone, fluoxetine,
and ferrous sulfate. Use among residents not taking a high-risk medication at hospitalization
differed. Among these residents, clonidine, promethazine, and acetaminophen/propoxyphene
napsylate (removed from the U.S. market in 2010) were the most prescribed high-risk
medications three days following nursing home readmission. By day 30 after nursing home
readmission, prescriptions for promethazine were less frequent for these residents, while
prescriptions for ferrous sulfate were relatively more prominent than at day 3.
DISCUSSION
Approximately one in five hospitalized nursing home residents had some high-risk
medication use on the day before hospitalization, a proportion that was remarkably
consistent in the 30 days before residents were hospitalized and after they returned to the
nursing home. Even though fewer than half of the residents who were using high-risk
medications at hospitalization received prescriptions for them again in the initial days after
nursing home readmission, this proportion increased to around 60% over the subsequent 30
days. Among residents who did not have a prescription for a high-risk medication at
hospitalization, 14% received a prescription for one of these drugs in the initial days after
their nursing home readmission, with this rate falling slightly and then remaining stable over
the subsequent 30 days in the nursing home.
These results confirm that high-risk medication use is an important clinical challenge for
nursing homes. They also suggest that nursing home prescribing practices play an important
role in shaping such use among hospitalized residents in the weeks after their readmission to
the nursing home.
Our study is one of the first to detail medication use by nursing home residents before and
after their hospitalization. It takes advantage of data showing all prescription drugs
dispensed in nursing homes regardless of payer, including those that are reimbursed within
Medicare’s bundled payment for care delivered during a skilled nursing facility stay.
Although the limited research literature examining medication reconciliation between the
hospital and nursing home finds significant discrepancies across settings,(3, 8–10, 17, 18)
we take advantage of data that include a large cohort of residents nationwide to compare
medication use before and after hospitalization. Moreover, focusing on high-risk medication
use offers insights about the quality of prescribing as residents transition across settings and,
more specifically, about the role of nursing homes in shaping these prescribing practices.
Nursing home residents transitioning back to the facility after hospitalization could have
returned taking additional medications, including a greater number of potentially
inappropriate or high-risk medications. If so, these medications could be tapered and
discontinued over time following their return to the home. Although we are unable to
observe medications prescribed during residents’ hospital stays, our results are not
consistent with this scenario. Around 60% of residents who were taking a high-risk
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medication during the pre-hospitalization period were again taking one by 30 days following
their readmission to the nursing home, even though fewer than half were taking these drugs
upon initial nursing home readmission. In addition, a persistent minority of residents who
did not have high-risk medication use prior to their hospital stay were taking high-risk
prescriptions during the post-nursing home readmission period. This might signal high-risk
medication use that was initiated in the hospital, but usage levels remained relatively steady
over the subsequent 30-day period.
Our aim in defining high-risk medication use using the 2003 Beers criteria is to focus on a
group of medications for which there was general consensus at the time of the study about
their potential inappropriateness, independent of residents’ diagnoses or conditions. Except
in limited circumstances, neither nursing homes nor hospitals should have continued,
started, or re-started these medications, even with (and perhaps especially with) the change
in status that a hospitalization implied. Consequently, it is concerning to see both the
moderate use of these medications prior to resident hospitalizations and the pull of residents
back onto these drugs following their nursing home readmission. Nonetheless, there are
situations where selective use of high-risk medications can be indicated. For example,
amiodarone, one of the more frequently prescribed high-risk medications we observe, is a
therapy that can be judiciously used to treat supraventricular arrhythmias effectively in
patients with heart failure.(19)
Although the temporal focus of our study is at the nexus of nursing home residents’
transitions to and from the hospital, our data and results focus more squarely on care
provided in the nursing home. It is possible – and perhaps even likely(11, 12) – that the
coordination of medication use between hospitals and nursing homes is poor, yet the
problem our results identify is not primarily one of coordination. Even when interrupted by a
hospital stay and accompanied by a subsequent decline in use, high-risk medication use
generally recurred once residents were settled back into the nursing home. Consequently,
although efforts to improve communication and rationalize financial incentives across
settings of care (e.g., bundled payment initiatives) may improve the quality of prescribing
along other margins, it is unclear whether such efforts would markedly impact the
prescribing patterns we identified. Instead, either increased oversight of prescribing by
regulators, payers, and providers may be needed or quality bonus payments such as the Star
program in Medicare Advantage may be useful. The recent scrutiny of antipsychotic
prescribing offers one potential model, as antipsychotic use rates have dropped dramatically
in the context of greater regulatory oversight, increased Part D coverage restrictions, and
bolstered quality improvement efforts on the part of providers.(7)
Our study has several limitations. We do not observe residents’ medication use while they
were in the hospital. We infer that residents’ medication use immediately after hospital
discharge and upon nursing home readmission reflected their clinical regimen in the
hospital, especially when compared to prior and subsequent usage patterns that were
ostensibly more under the nursing home’s control. However, given hospital/nursing home
medication reconciliation challenges identified in the research literature, there is likely some
imprecision in this inference. Although Beers criteria have gained wide acceptance over the
past two decades, they are not meant to regulate practice in a manner that supersedes the
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clinical judgment and the assessment of a patient’s physician. We also do not observe
whether any adverse health events occurred among residents who use high-risk medications.
On the other hand, the Beers criteria do not identify the universe of inappropriate
prescribing, because defining such practices by a list of medications rather than other
mechanisms may miss problems such as underuse and drug-drug interactions.
Our results are based on data from 2008 and reflect the policy and clinical environments at
that time. Even though nursing home prescribing continues to be a persistent challenge for
providers, regulators, and policymakers, our results could differ with more recent data or a
more recent listing of high-risk medications. Moreover, the Centers for Medicare and
Medicaid Services recently proposed tracking the use of high-risk medications as part of the
Part D plan STAR quality ratings for 2014,(20) a move that can be further bolstered by
plans’ own internal monitoring of these drugs and plan design and payment review features
to limit their use.(21) Finally, although our analyses include a large sample of nursing home
residents nationwide, the data come from a single long-term care pharmacy; generalizing our
findings to the nursing home sector as a whole should be done with caution.
In summary, our findings identify moderate levels of high-risk medication use by
hospitalized nursing home residents both before and after their hospital stays, at least as of
2008. Although some high-risk medication use may have been initiated during the hospital
stay, nursing homes seem to have played a role in driving the use of such medications by
hospitalized residents who return to the facility. Broader trends in the use of high-risk
medications following nursing home readmission represent an important clinical challenge
that policymakers and providers should seek to address to ensure the health and safety of
residents.
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Figure 1. High-Risk Medication Use among Hospitalized Nursing Home Residents Readmitted to
the Same Nursing Home, 30 Days Pre/Post, 2008
This figure shows high-risk medication use 30 days before a hospitalization and 30 days
after readmission to the same nursing home, among all hospitalized residents.
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Figure 2. High-Risk Medication Use among Hospitalized NH Residents Readmitted to the Same
NH, 30 Days Pre/Post, by Pre-Hospitalization HRM Use Status (Y/N) 2008
This figure displays high-risk medication use 30 days before hospitalization and 30 days
after readmission to the same nursing home, presented separately for people with and
without high-risk medication use on the day before hospitalization.
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Table 1
Characteristics for Elderly Dual Eligible Nursing Home Residents Who Were Hospitalized and Returned to





   Female




   65–74
   75–84
   85–94






   White
   Black




Hospital length-of-stay, days (sd)
Major diagnostic categories at admission to hospital
     Diseases and disorders of the respiratory system
     Diseases and disorders of the circulatory system
     Diseases and disorders of the kidney and urinary tract
     Diseases and disorders of the digestive system
Discharged to Medicare skilled nursing facility stay (%)
Total medications on the day before hospitalization (sd)









Note: All residents reside in nursing homes that contracted with Omnicare as their long-term care pharmacy provider. Study cohort includes
nursing home residents who were hospitalized and returned to the same nursing home following hospitalization in 2008 and who resided in the
nursing home for 30 days following readmission.
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